Pancreatic Cancer Research

ResearcherUniversity College HospitalActive in the last 2 years

Stephen P. Pereira

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0821-1809; OpenAlex author ID A5066537961. Sources: ClinicalTrials.gov.

Their work

Papers
35 (first author 2, last author 7)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
142
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: 2 papers · 2015: 6 papers, 1 trial · 2016: 3 papers · 2017: 2 papers · 2018: 1 paper · 2019: 3 papers · 2020: 2 papers · 2021: 5 papers · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 2 papers · 2026: 4 papers

Papers 35

  1. Identification of serum protein biomarkers for pre-cancerous lesions associated with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/1878-0261.70213↗
  2. Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the European Registry of Hereditary Pancreat… Co-author DOI 10.1016/j.ejca.2026.116592↗
  3. Editorial Note: Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint. Last author DOI 10.18632/oncotarget.28902↗
  4. High-fat diet imprints a macrophage-tumor CAMP-P2RX7 axis driving pancreatic cancer initiation, plasticity and metastasis Co-author DOI 10.64898/2026.02.10.703309↗
  5. Development and validation of a diagnostic prediction model for pancreatic ductal adenocarcinoma: VAPOR 1, protocol for a prospective multicentre case-control … Co-author DOI 10.1136/bmjopen-2024-094505↗
  6. Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Adenocarcinoma: A Scoping Review with Meta-Analysis. Co-author DOI 10.3390/diagnostics15040437↗
  7. Identification of a serum proteomic biomarker panel using diagnosis specific ensemble learning and symptoms for early pancreatic cancer detection. Last author DOI 10.1371/journal.pcbi.1012408↗
  8. Evaluation of urinary C-reactive protein as an early detection biomarker for pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2024.1450326↗
  9. Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes. Co-author DOI 10.1016/j.ebiom.2021.103802↗
  10. EUS-guided verteporfin photodynamic therapy for pancreatic cancer. First author DOI 10.1016/j.gie.2021.02.027↗
  11. 5-Aminolevulinic acid for fluorescence-guided surgery in pancreatic cancer: Cellular transport and fluorescence quantification studies. Last author DOI 10.1016/j.tranon.2020.100886↗
  12. Smart Nanoparticles as Advanced Anti-Akt Kinase Delivery Systems for Pancreatic Cancer Therapy. Co-author DOI 10.1021/acsami.1c14592↗
  13. Predicting risk of pancreatic cancer in individuals with new-onset type-2 diabetes in primary care: protocol for the development and validation of a clinical p… Co-author DOI 10.1101/2021.12.22.21268161↗
  14. Can we screen for pancreatic cancer? Identifying a sub-population of patients at high risk of subsequent diagnosis using machine learning techniques applied to… Co-author DOI 10.1371/journal.pone.0251876↗
  15. Early detection of pancreatic cancer. Co-author DOI 10.1016/s2468-1253(19)30416-9↗
  16. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study. Co-author DOI 10.1371/journal.pmed.1003489↗
  17. Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer. Co-author DOI 10.1038/s41395-018-0395-y↗
  18. Targeting Pyruvate Kinase M2 and Lactate Dehydrogenase A Is an Effective Combination Strategy for the Treatment of Pancreatic Cancer. Last author DOI 10.3390/cancers11091372↗
  19. Changes in tumor vascularity depicted by contrast-enhanced EUS as a predictor of prognosis and treatment efficacy in patients with unresectable pancreatic canc… Co-author DOI 10.4103/eus.eus_16_19↗
  20. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-gluco… Co-author DOI 10.3310/hta22070↗
  21. Ex Vivo PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients. Co-author DOI 10.1158/1078-0432.ccr-17-1185↗
  22. Evidence of Altered Glycosylation of Serum Proteins Prior to Pancreatic Cancer Diagnosis. Co-author DOI 10.3390/ijms18122670↗
  23. Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. Co-author DOI 10.1158/1078-0432.ccr-15-0879↗
  24. Pyruvate Kinase M2 and Lactate Dehydrogenase A Are Overexpressed in Pancreatic Cancer and Correlate with Poor Outcome. Last author DOI 10.1371/journal.pone.0151635↗
  25. Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint. Last author DOI 10.18632/oncotarget.7611↗
  26. Perfusion CT estimates photosensitizer uptake and biodistribution in a rabbit orthotopic pancreatic cancer model: a pilot study. Co-author DOI 10.1016/j.acra.2014.12.014↗
  27. Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer. Co-author DOI 10.1016/j.jprot.2014.10.001↗
  28. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Co-author DOI 10.1158/1078-0432.ccr-14-0365↗
  29. Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-14-2467↗
  30. Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models. Co-author DOI 10.18632/oncotarget.4186↗
  31. Noninvasive urinary miRNA biomarkers for early detection of pancreatic adenocarcinoma. Co-author PMID 26807325↗
  32. Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Last author DOI 10.1038/bjc.2014.95↗
  33. CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy. Co-author DOI 10.1088/0031-9155/59/8/1911↗
  34. Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines. Co-author DOI 10.1002/lsm.21093↗
  35. Diagnosing and managing pancreatic cancer. First author PMID 21932502↗

Trials 1

  1. Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions Principal investigator NCT02494388↗

Closest collaborators

The 25 strongest of 142 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eithne Costello · 11 shared papers, 2015–2026 · strength 1.15
  2. Pilar Acedo · 5 shared papers, 2019–2026 · strength 0.93
  3. Christopher Michael Halloran · 6 shared papers, 2018–2026 · strength 0.75
  4. William Greenhalf · 8 shared papers, 2015–2026 · strength 0.75
  5. Oleg B. Blyuss · 4 shared papers, 2015–2024 · strength 0.52
  6. Matthew Thomas Huggett · 5 shared papers, 2011–2026 · strength 0.52
  7. Paula Ghaneh · 4 shared papers, 2018–2026 · strength 0.48
  8. Margaret Geraldine Keane · 3 shared papers, 2016–2026 · strength 0.47
  9. Zaed Z. R. Hamady · 3 shared papers, 2019–2026 · strength 0.46
  10. Hemant Mahendrakumar Kocher · 5 shared papers, 2015–2025 · strength 0.40
  11. Alexander Ney · 3 shared papers, 2020–2024 · strength 0.38
  12. Tatjana Crnogorac‐Jurcevic · 4 shared papers, 2015–2024 · strength 0.38
  13. Andrew Malvern Smith · 3 shared papers, 2018–2026 · strength 0.34
  14. John F. Timms · 5 shared papers, 2015–2022 · strength 0.34
  15. Silvana Debernardi · 3 shared papers, 2015–2024 · strength 0.34
  16. Mariana Jinga · 2 shared papers, 2019–2025 · strength 0.34
  17. Adrian Săftoiu · 2 shared papers, 2019–2025 · strength 0.34
  18. Tayyaba Hasan · 5 shared papers, 2011–2021 · strength 0.30
  19. Stephen Jacob Pandol · 2 shared papers, 2020–2024 · strength 0.30
  20. Guruprasad Padur Aithal · 2 shared papers, 2019–2026 · strength 0.29
  21. Kofi W. Oppong · 2 shared papers, 2019–2026 · strength 0.29
  22. Hannah Mearns · 1 shared paper, 2026 · strength 0.28
  23. Sara R. Zanivan · 1 shared paper, 2026 · strength 0.28
  24. Kevin M. Ryan · 1 shared paper, 2026 · strength 0.28
  25. Lucy S. Oldfield · 3 shared papers, 2016–2022 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.